NCT06671483

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,088 (estimated)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Conditions

• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	Zasocitinib	Zasocitinib over-encapsulated tablets.
DRUG	Active Comparator	Active comparator capsule.
DRUG	Placebo	Zasocitinib or active comparator matching placebo.

Timeline

• Start date: 2025-03-03
• Primary completion: 2027-05-18
• Completion: 2028-01-28
• First posted: 2024-11-04
• Last updated: 2026-04-06

Locations

189 sites across 20 countries: United States, Belgium, Bulgaria, Chile, Croatia, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, Mexico, New Zealand, Poland, Portugal, Puerto Rico, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study